Elara, Mochi, and Noom all help women lose weight, but they are built on three different models. Elara is a women-focused medical program with all-inclusive cash pricing (medication, provider visit, shipping, and support in one price). Mochi is an insurance-forward telehealth membership that prices the visit and the medication separately. Noom is a behavior-change app at its core, with an optional medical layer (Noom Med) that can prescribe medication. This guide compares how each one works, what it costs, and who each fits best, with the numbers verified as of publication.
Key takeaways
- Elara: women-first medical program; compounded semaglutide from $247/month and compounded tirzepatide from $355/month, all-inclusive; cash-pay, no membership fee, no insurance hassle.
- Mochi: medical telehealth with an insurance option; membership fee plus medication priced separately; works with insurance for brand-name GLP-1s.
- Noom: started as a psychology-based coaching app; Noom Med adds licensed clinicians who can prescribe GLP-1s, metformin, or other medications.
- "Cheapest" depends on what's included, an all-in price and a low sticker price are not the same thing. Read what each program bundles before you compare.
- Compounded medications are not FDA-approved. Any GLP-1 you take should be prescribed and monitored by a licensed provider.
How are Elara, Mochi, and Noom different?
The biggest difference is the model, not the medication. All three can connect you with a GLP-1 like semaglutide or tirzepatide, but they package the care and the cost very differently.
- Elara is medical-first and women-first. A licensed provider reviews every patient, and if a GLP-1 is appropriate, the medication, visit, shipping, and ongoing support are bundled into one all-inclusive price, plus supporting options like B12 and lipotropic injections, an app, and 7-day-a-week human support.
- Mochi Health is medical-first and insurance-forward. You pay a monthly membership for access to board-certified physicians and dietitians, and pay for the medication on top of that. Mochi also offers an insurance-linked plan and handles prior authorizations for brand-name GLP-1s. [1]
- Noom began as a coaching-first app built around behavior change and food psychology. Noom Med is its clinical add-on: after an intake survey, a licensed clinician can prescribe a GLP-1 or another weight-loss medication if it's appropriate for you. [2]
None of the three is "just an app," and none is purely a pharmacy. The real question is which combination of medical care, coaching, price structure, and women-specific focus fits what you need.
Side-by-side comparison
The table below reflects publicly available information as of July 2026. Competitor pricing and policies change often, so verify current terms on each provider's own site before you enroll.
| Elara | Mochi Health | Noom (Noom Med) | |
|---|---|---|---|
| Core model | Women's medical weight-loss program | Insurance-forward medical telehealth | Behavior-change app + coaching, with a medical add-on |
| Who reviews you | Licensed provider reviews every patient | Board-certified physicians + dietitians | Licensed clinician (Noom Med) |
| GLP-1 options | Compounded semaglutide & tirzepatide; branded Wegovy, Zepbound, Ozempic, Mounjaro* | Compounded GLP-1s; branded Wegovy, Zepbound, Saxenda [1] | Prescribes GLP-1s, metformin, or other meds; brand-name filled at your pharmacy [2] |
| Pricing structure | All-inclusive (medication + visit + shipping + support), no separate membership | Membership fee + medication priced separately | Subscription tiers; medication cost varies by plan |
| Starting price (verify current) | Compounded semaglutide $247/mo, tirzepatide $355/mo, all-in | Membership from ~$79/mo plus compounded from ~$99/mo [1] | GLP-1 programs roughly $199-$299/mo; lower-dose "microdose" from ~$79 for the first supply [2] |
| Insurance | Cash-pay only (no insurance billing) | Cash-pay or insurance option for eligible members [1] | Depends on tier; brand-name billed at your pharmacy [2] |
| Women-specific focus | Yes, female physiology, PCOS, menopause, adjuncts | General audience | General audience |
| Extras | App, recipes, workouts, private community, 7-day support | Dietitian access | Psychology-based coaching, food logging |
\Only Wegovy and Zepbound are FDA-approved for chronic weight management. Ozempic and Mounjaro are FDA-approved for type 2 diabetes; using them for weight loss is off-label*.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.
Which one is cheapest?
It depends on how you count, because the three programs bundle costs differently. A low headline price with add-ons can end up higher than an all-inclusive price.
- Elara puts everything in one number: compounded semaglutide starts at $247/month (dropping to about $198/month on the 12-month plan) and compounded tirzepatide starts at $355/month (about $298/month on the 12-month plan). That price includes the provider visit, the medication, shipping, and ongoing support, there's no separate membership fee.
- Mochi splits the cost: a membership (from about $79/month as of publication) plus the medication (compounded GLP-1s advertised from about $99/month), so a compounded-semaglutide total lands near $178/month before any promotions. Brand-name medication runs through insurance or your pharmacy separately. [1]
- Noom's medical programs run roughly $199-$299/month as of publication for its GLP-1 plans (billed quarterly), with a lower-dose "microdose" option from about $79 for the first four-week supply; if you choose brand-name medication, you pay for that at your own pharmacy on top of the program fee. Verify current tiers before enrolling. [2]
So on a like-for-like compounded-semaglutide basis, the three land in a similar range, the meaningful differences are what's included, how transparent the pricing is, and whether the program is built around women. For the full breakdown of brand vs. compounded math, see Elara's guide to semaglutide cost in 2026.
For context on brand-name pricing: Wegovy lists at roughly $1,349/month, though manufacturer savings and self-pay programs can lower that for eligible patients. [3] Elara never claims its compounded medication is the same as, or a substitute for, a branded drug, it's a different, non-FDA-approved product prepared by a licensed compounding pharmacy.
Why does the "coaching vs. medical" difference matter?
Because it changes what you're actually buying.
Noom's strength is behavior change, food logging, psychology-based lessons, and coaching, with Noom Med layering a clinician on top when medication is appropriate. If you want an app-first experience with coaching baked in, that model may appeal to you. [2] Mochi leads with clinical access and insurance navigation; if you have coverage that might pay for a brand-name GLP-1, its handling of prior authorizations can be a real advantage. [1]
Elara is medical-first and women-first, designed around the questions women actually ask, like how a GLP-1 interacts with PCOS, perimenopause and menopause, birth control, and fertility plans. If you want your weight-loss care to account for female physiology from the start, that focus is the differentiator.
There's no single "best", there's a best fit. If you're also weighing the bigger general-audience brands, see Elara vs Hers and Elara vs Ro, or, since the name comes up, Elara vs. ElaraMD (a separate company).
What should every woman check before enrolling in any of them?
The FDA and FTC have made 2026 a serious year for telehealth weight-loss marketing. The FTC finalized a deceptive-marketing order against telehealth GLP-1 seller NextMed in December 2025 over hidden costs and fake testimonials. [4] Use that as your checklist, whichever program you choose:
- A licensed provider reviews you before any prescription, not a form that dispenses on autopilot.
- The medication comes from a US state-licensed pharmacy, and the program is upfront about compounded vs. brand-name.
- Pricing is transparent, with the full cost and any recurring charges shown before you pay.
- Real safety information is provided, including who should not take a GLP-1.
- No miracle claims, no before/after promises, no "results not typical" fine print.
On the regulatory backdrop: the semaglutide and tirzepatide shortages were declared resolved (tirzepatide December 2024, semaglutide February 2025), and mass shortage-based compounding wound down in 2025. Narrow, patient-specific compounding continues when a licensed clinician documents a clinical need. [5] Separately, in April 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B "bulks" list; the FDA extended the public comment period to July 30, 2026. This is a proposal, not a final rule, so the compounding landscape may change. [6]
A note on GLP-1 safety
Whichever program you pick, GLP-1 medications carry real risks. They come with a boxed warning for thyroid C-cell tumors and are contraindicated if you or a family member has a history of medullary thyroid carcinoma or MEN 2. Other cautions include pancreatitis, gallbladder problems, and significant GI side effects, and GLP-1s are not recommended during pregnancy or breastfeeding. [7] This is not a complete list. Talk to a licensed provider about your history before starting, and review the FDA prescribing information for whatever medication you're prescribed.
How Elara helps
Elara is a women's weight-loss program built for those who want medical care without the guesswork, the insurance runaround, or the surprise fees. A licensed provider reviews every patient, and if a GLP-1 is appropriate, you get one all-inclusive price: the medication, the visit, shipping, ongoing access to Elara's medical team, the private community, the app, recipes, and workouts. Elara serves all 50 states plus Puerto Rico, is cash-pay (no insurance hurdles or denials), and offers 7-day-a-week human support. For women who want them, supporting options like B12 or lipotropic injections are available alongside the program.
**See Elara's compounded semaglutide plans, from $247/month, all-in (medication, provider visit, and shipping included), or compounded tirzepatide from $355/month. A licensed provider reviews every patient. Compounded medications are not FDA-approved.** You can also start with Elara's free eligibility check.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.
Frequently asked questions
Elara vs Noom, which is better for women?
They solve different problems. Noom leads with behavior-change coaching and adds a medical layer (Noom Med) that can prescribe medication. Elara is a medical-first, women-first program with all-inclusive cash pricing and support built around female physiology like PCOS and menopause. If you want women-focused medical care in one price, Elara fits; if you want app-based coaching, Noom fits.
Elara vs Mochi, what's the difference?
Both are medical telehealth programs, but they price care differently. Mochi charges a membership fee plus the medication separately and offers an insurance-linked option, which can help if you have coverage for brand-name GLP-1s. Elara bundles the medication, provider visit, shipping, and support into one all-inclusive cash price and centers women's health. Verify each program's current terms before enrolling.
Which program is cheapest?
It depends on what's included. Elara's all-inclusive compounded semaglutide starts at $247/month; Mochi's membership plus compounded medication totals near $178/month as of publication; Noom's GLP-1 programs run roughly $199-$299/month (with a lower-dose microdose option from about $79 for the first supply). On a like-for-like compounded basis they're similar, so compare what each price actually covers, not just the sticker number.
Is Noom just an app, or does it prescribe medication?
Both. Noom started as a psychology-based coaching app for behavior change. Noom Med is its clinical service: after an intake survey, a licensed clinician can prescribe a GLP-1, metformin, or another weight-loss medication if it's clinically appropriate, with ongoing monitoring through the app.
Which is best for women specifically?
Elara is the only one of the three built specifically around women's physiology, how GLP-1s interact with PCOS, perimenopause, menopause, birth control, and pregnancy planning, with supporting options and an all-inclusive price. Mochi and Noom serve a general audience. "Best" still depends on your priorities: coaching, insurance, or women-focused medical care.
Do all three offer compounded medication?
As of publication, each has offered compounded GLP-1s, but the regulatory landscape is shifting and terms change, verify current offerings on each provider's own site. Compounded semaglutide and tirzepatide are prepared by state-licensed compounding pharmacies and prescribed by a clinician when appropriate. Compounded medications are not FDA-approved.
The bottom line
Elara, Mochi, and Noom all connect women with GLP-1 care, but they're three different models: Elara is women-first medical care at one all-inclusive cash price, Mochi is insurance-forward telehealth that prices the visit and medication separately, and Noom is coaching-first with a medical add-on. Compare what each price actually includes, confirm a licensed provider reviews you, and remember that compounded medications are not FDA-approved. Talk to a licensed clinician about what's right for your body and your history.
References
- Mochi Health. "Telehealth for Weight Loss, Hair Loss, Skin & More." https://joinmochi.com/
- Noom. "Noom Med Plans & Pricing | GLP-1 & Weight Loss Programs." https://www.noom.com/med/pricing/
- NovoCare. "Wegovy (semaglutide) Cost, Coverage, & Savings Resources." https://www.novocare.com/patient/medicines/wegovy.html
- Federal Trade Commission. "FTC Approves Final Order against Telehealth Provider NextMed Over Charges It Used Deceptive Advertising Claims to Sell GLP-1 Weight-Loss Programs." https://www.ftc.gov/news-events/news/press-releases/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-over-charges-it-used-deceptive
- U.S. Food & Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food & Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- DailyMed (U.S. National Library of Medicine). "Label: Wegovy, semaglutide injection, solution." https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564
This article is for general education and is not medical advice. Talk to a licensed clinician about your situation.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.